MetaCap

Amphastar Pharmaceuticals (AMPH) vs Ocular Therapeutix (OCUL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Amphastar Pharmaceuticals (AMPH) has outperformed Ocular Therapeutix (OCUL) over the past year, gaining 8.6% versus a loss of 54.5%. Over five years, AMPH leads with a +41.9% price change compared with -14.8% for OCUL. Ocular Therapeutix is the larger company by market cap ($1.23 billion vs $1.20 billion), about 1.0 times the size, while Amphastar Pharmaceuticals is growing revenue faster (-1.7% vs -18.5%).

Amphastar Pharmaceuticals converts more of its revenue into profit, with a net margin of 13.6% versus -511.9%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AMPH+8.61%OCUL-54.49%
+36%-11%-59%
Nov 21, 20251 yearNov 20, 2026
AMPH+37.74%OCUL-16.74%
+220%+69%-82%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AMPH versus OCUL key metrics
MetricAMPHOCUL
Share price$28.25$5.57
Market cap$1.20B$1.23B
1-day change+0.50%-4.95%
YTD return+5.49%-54.12%
1-year return+8.61%-54.49%
5-year return+41.89%-14.83%
P/E ratio (TTM)12.96—
Forward P/E8.43—
EPS (TTM)$2.18$-1.44
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$719.89M$51.95M
Revenue growth (YoY)-1.65%-18.47%
Net income (latest FY)$98.09M$-265.94M
Gross margin49.46%87.35%
Operating margin19.50%-519.75%
Net margin13.63%-511.90%
52-week high$31.00$16.44
52-week low$16.65$5.54
Distance from 52-week high-8.87%-66.12%
Analyst consensusholdstrong_buy
Avg. price target upside-13.27%+361.94%
Average volume475.35K3.03M
Shares outstanding42.65M220.02M
Employees1,976325
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • AMPH has outperformed OCUL by 63.1 percentage points over the past year.
  • Amphastar Pharmaceuticals is more profitable, keeping 13.6 cents of every revenue dollar as net income versus -511.9 cents for Ocular Therapeutix.
  • Amphastar Pharmaceuticals grew revenue faster in its latest fiscal year (-1.65% vs -18.47%).

About Amphastar Pharmaceuticals

AMPH stock →

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose.

Health Care · Biotechnology: Pharmaceutical Preparations · 1,976 employees

About Ocular Therapeutix

OCUL stock →

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.

Health Care · Biotechnology: Pharmaceutical Preparations · 325 employees

AMPH vs OCUL FAQ

Which is bigger, Amphastar Pharmaceuticals or Ocular Therapeutix?

Ocular Therapeutix (OCUL) is larger, with a market capitalization of $1.23B compared with $1.20B for Amphastar Pharmaceuticals (AMPH).

Which stock has performed better over the past year, AMPH or OCUL?

AMPH returned +8.61% over the past 12 months, compared with -54.49% for OCUL (price return, excluding dividends). Past performance does not predict future results.

Are Amphastar Pharmaceuticals and Ocular Therapeutix in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons